27589720|t|Ruscogenin Attenuates Cerebral Ischemia -Induced Blood-Brain Barrier Dysfunction by Suppressing TXNIP / NLRP3 Inflammasome Activation and the MAPK Pathway
27589720|a|Ruscogenin, an important steroid sapogenin derived from Ophiopogon japonicus, has been shown to inhibit cerebral ischemic injury. However, its potential molecular action on blood-brain barrier (BBB) dysfunction after stroke remains unclear. This study aimed to investigate the effects of ruscogenin on BBB dysfunction and the underlying mechanisms in middle cerebral artery occlusion / reperfusion (MCAO / R)- injured mice and oxygen-glucose deprivation / reoxygenation (OGD / R)- injured mouse brain microvascular endothelial cells (bEnd.3). The results demonstrated that administration of ruscogenin (10 mg/kg) decreased the brain infarction and edema, improved neurological deficits, increased cerebral brain flow (CBF), ameliorated histopathological damage, reduced evans blue (EB) leakage and upregulated the expression of tight junctions (TJs) in MCAO / R - injured mice. Meanwhile, ruscogenin (0.1-10 µM) treatment increased cell viability and trans-endothelial electrical resistance (TEER) value, decreased sodium fluorescein leakage, and modulated the TJs expression in OGD / R -induced bEnd.3 cells. Moreover, ruscogenin also inhibited the expression of interleukin-1β (IL-1β) and caspase-1, and markedly suppressed the expression of Nucleotide-binding domain (NOD)-like receptor family, pyrin domain containing 3 (NLRP3) and thiredoxin-interactive protein (TXNIP) in vivo and in vitro. Furthermore, ruscogenin decreased reactive oxygen species (ROS) generation and inhibited the mitogen-activated protein kinase (MAPK) pathway in OGD / R -induced bEnd.3 cells. Our findings provide some new insights into its potential application for the prevention and treatment of ischemic stroke.
27589720	0	10	Ruscogenin	T103	UMLS:C0073709
27589720	22	39	Cerebral Ischemia	T038	UMLS:C0917798
27589720	49	68	Blood-Brain Barrier	T017	UMLS:C0005854
27589720	96	101	TXNIP	T103	UMLS:C1448239
27589720	104	133	NLRP3 Inflammasome Activation	T038	UMLS:C3272080
27589720	142	154	MAPK Pathway	T038	UMLS:C1518102
27589720	155	165	Ruscogenin	T103	UMLS:C0073709
27589720	180	187	steroid	T103	UMLS:C0038317
27589720	188	197	sapogenin	T103	UMLS:C0072845
27589720	211	231	Ophiopogon japonicus	T204	UMLS:C1046253
27589720	308	324	molecular action	T038	UMLS:C1148560
27589720	328	347	blood-brain barrier	T017	UMLS:C0005854
27589720	349	352	BBB	T017	UMLS:C0005854
27589720	372	378	stroke	T038	UMLS:C0038454
27589720	401	406	study	T062	UMLS:C2603343
27589720	443	453	ruscogenin	T103	UMLS:C0073709
27589720	457	460	BBB	T017	UMLS:C0005854
27589720	506	538	middle cerebral artery occlusion	T017	UMLS:C0740391
27589720	541	552	reperfusion	T037	UMLS:C3854511
27589720	554	558	MCAO	T017	UMLS:C0740391
27589720	561	562	R	T037	UMLS:C3854511
27589720	573	577	mice	T204	UMLS:C0026809
27589720	582	608	oxygen-glucose deprivation	T038	UMLS:C4236781
27589720	626	629	OGD	T038	UMLS:C4236781
27589720	644	649	mouse	T204	UMLS:C0026809
27589720	650	655	brain	T017	UMLS:C0006104
27589720	670	687	endothelial cells	T017	UMLS:C0225336
27589720	689	695	bEnd.3	T017	UMLS:C0225336
27589720	728	742	administration	T058	UMLS:C1533734
27589720	746	756	ruscogenin	T103	UMLS:C0073709
27589720	782	798	brain infarction	T038	UMLS:C0751955
27589720	803	808	edema	T033	UMLS:C0013604
27589720	810	818	improved	T033	UMLS:C0184511
27589720	819	840	neurological deficits	T033	UMLS:C0521654
27589720	852	871	cerebral brain flow	T033	UMLS:C0428714
27589720	873	876	CBF	T033	UMLS:C0428714
27589720	879	890	ameliorated	T033	UMLS:C0184511
27589720	909	915	damage	T037	UMLS:C0010957
27589720	925	935	evans blue	T103	UMLS:C0015205
27589720	937	939	EB	T103	UMLS:C0015205
27589720	941	948	leakage	T033	UMLS:C4281748
27589720	953	964	upregulated	T038	UMLS:C0041904
27589720	969	979	expression	T038	UMLS:C1171362
27589720	983	998	tight junctions	T103	UMLS:C3494363
27589720	1000	1003	TJs	T103	UMLS:C3494363
27589720	1008	1012	MCAO	T017	UMLS:C0740391
27589720	1015	1016	R	T037	UMLS:C3854511
27589720	1027	1031	mice	T204	UMLS:C0026809
27589720	1044	1054	ruscogenin	T103	UMLS:C0073709
27589720	1067	1076	treatment	T058	UMLS:C0087111
27589720	1087	1101	cell viability	T038	UMLS:C0007620
27589720	1170	1188	sodium fluorescein	T103	UMLS:C0147866
27589720	1189	1196	leakage	T033	UMLS:C4281748
27589720	1202	1211	modulated	T082	UMLS:C0443264
27589720	1216	1219	TJs	T103	UMLS:C3494363
27589720	1220	1230	expression	T038	UMLS:C1171362
27589720	1234	1237	OGD	T038	UMLS:C4236781
27589720	1251	1263	bEnd.3 cells	T017	UMLS:C0225336
27589720	1275	1285	ruscogenin	T103	UMLS:C0073709
27589720	1305	1315	expression	T038	UMLS:C1171362
27589720	1319	1333	interleukin-1β	T103	UMLS:C0021753
27589720	1335	1340	IL-1β	T103	UMLS:C0021753
27589720	1346	1355	caspase-1	T103	UMLS:C0534519
27589720	1385	1395	expression	T038	UMLS:C1171362
27589720	1399	1478	Nucleotide-binding domain (NOD)-like receptor family, pyrin domain containing 3	T103	UMLS:C4255055
27589720	1480	1485	NLRP3	T103	UMLS:C1528260
27589720	1491	1521	thiredoxin-interactive protein	T103	UMLS:C1448239
27589720	1523	1528	TXNIP	T103	UMLS:C1448239
27589720	1565	1575	ruscogenin	T103	UMLS:C0073709
27589720	1586	1609	reactive oxygen species	T103	UMLS:C0162772
27589720	1611	1614	ROS	T103	UMLS:C0162772
27589720	1645	1692	mitogen-activated protein kinase (MAPK) pathway	T038	UMLS:C1518102
27589720	1696	1699	OGD	T038	UMLS:C4236781
27589720	1713	1725	bEnd.3 cells	T017	UMLS:C0225336
27589720	1731	1739	findings	T033	UMLS:C0243095
27589720	1757	1765	insights	T038	UMLS:C0233820
27589720	1785	1796	application	T058	UMLS:C0185125
27589720	1805	1815	prevention	T058	UMLS:C0199176
27589720	1820	1829	treatment	T058	UMLS:C0087111
27589720	1833	1848	ischemic stroke	T038	UMLS:C0948008